MRUS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

8.49M

-7.07%

-1.060

+116.27%

10.85M

-59.03%

-1.288

-7.99%

10.52M

+19.16%

-1.232

-44.76%

Estimates Revision

The market is revising Upward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by 5.35% over the past three months. During the same period, the stock price has changed by -4.84%.

Revenue Estimates for FY2025

Revise Upward

+5.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.43%

In Past 3 Month

Stock Price

Go Down

-4.84%

In Past 3 Month

16 Analyst Rating

Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 97.71 USD with a low forecast of 92.00 USD and a high forecast of 112.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

14 Hold

0 Sell

Hold

Current: 0.000

Low

92.00

Averages

97.71

High

112.00

Current: 0.000

Low

92.00

Averages

97.71

High

112.00

Barclays

Overweight -> Equal Weight

downgrade

$112 -> $97

2025-09-30

Reason

Barclays

Price Target

$112 -> $97

2025-09-30

downgrade

Overweight -> Equal Weight

Reason

Barclays downgraded Merus (MRUS) to Equal Weight from Overweight with a price target of $97, down from $112, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm expects a timely deal closure and sees a low probability of another bidder.

BMO Capital

Evan Seigerman

Outperform -> Market Perform

downgrade

$110 -> $97

2025-09-30

Reason

BMO Capital

Evan Seigerman

Price Target

$110 -> $97

2025-09-30

downgrade

Outperform -> Market Perform

Reason

BMO Capital analyst Evan Seigerman downgraded Merus (MRUS) to Market Perform from Outperform with a price target of $97, down from $110, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm views the deal as a \"significant positive\" for shareholders.

UBS

Buy

Neutral

downgrade

$72 -> $97

2025-09-30

Reason

UBS

Price Target

$72 -> $97

2025-09-30

downgrade

Buy

Neutral

Reason

UBS downgraded Merus (MRUS) to Neutral from Buy with a price target of $97, up from $72, after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share. The firm sees limited overlap with Genmab's existing pipeline.

LifeSci Capital

Charles Zhu

Outperform

Market Perform

downgrade

$97

2025-09-29

Reason

LifeSci Capital

Charles Zhu

Price Target

$97

2025-09-29

downgrade

Outperform

Market Perform

Reason

LifeSci Capital analyst Charles Zhu downgraded Merus (MRUS) to Market Perform from Outperform with a $97 price target after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share

Needham

Ami Fadia

Buy -> Hold

downgrade

2025-09-29

Reason

Needham

Ami Fadia

Price Target

2025-09-29

downgrade

Buy -> Hold

Reason

Needham analyst Ami Fadia downgraded Merus to Hold from Buy without a price target after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97 per share in an all-cash transaction, representing a transaction value of $8B.

Wells Fargo

Eva Fortea Verdejo

Overweight -> Equal Weight

downgrade

$95 -> $97

2025-09-29

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

$95 -> $97

2025-09-29

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo analyst Eva Fortea Verdejo downgraded Merus (MRUS) to Equal Weight from Overweight with a price target of $97, up from $95, after the company entered into an agreement pursuant to which Genmab (GMAB) will acquire all the shares of Merus for $97 per share in an all-cash transaction, representing a transaction value of $8B.

Valuation Metrics

The current forward P/E ratio for Merus NV (MRUS.O) is -11.82, compared to its 5-year average forward P/E of -10.89. For a more detailed relative valuation and DCF analysis to assess Merus NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.89

Current PE

-11.82

Overvalued PE

-7.03

Undervalued PE

-14.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.23

Current EV/EBITDA

-8.67

Overvalued EV/EBITDA

-3.47

Undervalued EV/EBITDA

-10.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

52.91

Current PS

74.69

Overvalued PS

98.10

Undervalued PS

7.72

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MRUS News & Events

Events Timeline

No data

News

9.0

2025-12-16Newsfilter

Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer

9.0

2025-12-16PRnewswire

Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer

8.5

2025-12-12Globenewswire

Genmab Acquires Merus, Anticipates $1 Billion EBITDA by 2029

People Also Watch

Frequently Asked Questions

What is Merus NV (MRUS) stock price today?

The current price of MRUS is 0 USD — it has decreased -7.69 % in the last trading day.

What is Merus NV (MRUS)'s business?

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

What is the price predicton of MRUS Stock?

What is Merus NV (MRUS)'s revenue for the last quarter?

Merus NV revenue for the last quarter amounts to 12.15M USD, increased 3.21 % YoY.

What is Merus NV (MRUS)'s earnings per share (EPS) for the last quarter?

Merus NV. EPS for the last quarter amounts to -1.26 USD, decreased -13.70 % YoY.

What changes have occurred in the market's expectations for Merus NV (MRUS)'s fundamentals?

How many employees does Merus NV (MRUS). have?

Merus NV (MRUS) has 260 emplpoyees as of January 10 2026.

What is Merus NV (MRUS) market cap?

Today MRUS has the market capitalization of 4.06B USD.